In this podcast episode, Brennan Spiegel, MD, MSHS, discusses virtual and augmented reality in gastroenterology from both a clinical and research perspective, as well as his thoughts on the future of the field.
- Intro :02
- The interview :22
- How did you decide to be a doctor? :23
- What are your main takeaways from serving as editor of AJG over the last 6 years? 2:46
- What was your journey that led to what you’re focusing on now? 5:47
- Can you give us a sense of what these words mean when you say “virtual reality” and “augmented reality”? 7:29
- As a professor of medicine, a gastroenterologist, a public health advocate and researcher, how did you come to think of this being your area of focus? 10:40
- How does this work from a clinical perspective? 15:21
- Can you tell us about how the clinical trials are run, what sham VR is and how are these high-quality trials designed? 19:53
- Have we studied the biochemical response? 22:13
- The discussion of virtual reality and its use in neuromodulation and nerve stimulation 25:07
- Where do you think the biggest challenge is in this widespread implementation? 31:34
- What about developing VR reimbursement strategies … Have you heard of virtual reality companies approaching things this way? 34:44
- How do you think about intellectual property with VR? 37:38
- Where do you think we stand in regard to regulatory hurdles? 39:52
- Are there any risks? Are these things that are being studied? Are these valid concerns? 42:00
- What do you want the listeners to take away from this? What’s the call to action? 44:31
- Thank you, Dr. Spiegel 46:27
Brennan Spiegel, MD, MSHS, is the director of health services research for Cedars-Sinai and the director of the Cedars-Sinai Master's Degree Program in health delivery science. He directs the Cedars-Sinai Center for Outcomes Research and Education.
We’d love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on Twitter @HealioGastro @sameerkberry @umfoodoc
Disclosures: Berry, Chey and Spiegel report no relevant financial disclosures.
